Abstract:Objective To evaluate the curative effect of Alogliptin combined with motor imagery under hyperbaric oxygen on function impairment in diabetic patients with silent cerebral infarction (SCI). Methods Sixty newly-diagnosed type 2 diabetic patients complicated with SCI were included. The patients were divided into two treatment groups: Alogliptin treatment group (group A, n = 30) and Alogliptin combined with motor imagery under hyperbaric oxygen treatment group (group B, n = 30). The degree of neurological defects and Montreal Cognitive Assessment Scale (MoCA) scores were evaluated at baseline and 6 months after treatment. Serum GP VI and urine 11-DH-TXB2 levels were determined by ELISA. The expression of cytoskeleton microtubule associated protein (MAP-2) was determined by Western blot. Results Compared to the group A, the severity of neurofunctional defects, serum GP VI, 11-DH-TXB2 and MAP-2 levels were significantly lower in the group B (P < 0.05); while MoCA scores were higher in the group B, among which the visuospatial/executive function score, attention and concentration score, and comprehensive score in the group B significantly increased (P < 0.05). The sub-scores of calculation, abstract thinking, language competence, memory and orientation, and comprehensive score were also higher in the group B but the differences were not statistically significant (P > 0.05). Intra-group comparisons revealed a time-dependent effect of treatment. Conclusions The treatment of Alogliptin combined with motor imagery under hyperbaric oxygen can better promote thrombolysis and absorption of thrombi and recovery of brain damage, and improve neurocognitive function.